Akari Therapeutics to Present Data from Phase 2 PNH Trial of Coversin at the 22nd Congress of the European Hematology Association NEW YORK and LONDON

Akari Therapeutics to Present Data from

Phase 2 PNH Trial of Coversin at the 22nd Congress of the European Hematology Association

NEW YORK and LONDON, June 23, 2017

-- Akari Therapeutics (NASDAQ: AKTX), a clinical-stage biopharmaceutical company, is presenting a poster today at the 22nd Congress

of the European Hematology Association (EHA) in Madrid, Spain containing data for the four patients, to date, who have completed

its ongoing Phase 2 trial of Coversin in paroxysmal nocturnal hemoglobinuria (PNH). Coversin is a second-generation complement

inhibitor that is capable of being a self-administered subcutaneous injection.

The poster can be found here:

About Akari Therapeutics Plc

Akari is a clinical-stage biopharmaceutical

company focused on the development and commercialization of life-transforming treatments for a range of rare and orphan autoimmune

and inflammatory diseases caused by dysregulation of complement C5 and Leukotriene B4 (LTB4), including paroxysmal nocturnal hemoglobinuria

("PNH"), atypical Hemolytic Uremic Syndrome ("aHUS"), and Guillain Barr syndrome ("GBS").

Akari's lead product candidate, Coversin complement inhibitor, a second-generation complement inhibitor, has shown

it can act on complement component-C5, preventing the release of C5a and the formation of C5b-9 (also known as the membrane

attack complex or MAC), and independently also inhibits LTB4 activity. C5 inhibition is growing in importance in a range of rare

autoimmune diseases related to dysregulation of the complement component of the immune system, including PNH, aHUS, and GBS. Exploiting

the power of nature, Akari is also developing other tick derived proteins and expects to bring additional compounds to clinical

trials over the next several years. The pipeline is focused on developing bioengineered versions of native tick salivary proteins

that act as anti-inflammatory compounds allowing the tick to remain on its host. These compounds include PGP sparing LTB4 inhibitors,

classical and alternative complement inhibitors, anti-histamines, and serotonin inhibitors as examples. Akari is also developing

engineered forms that allow for potential oral absorption, as, for example, a potential orally absorbed C5 inhibitor, and tissue

specific proteins, as, for example, Coversin that acts specifically at the neuromuscular junction for diseases like myasthenia

Cautionary Note Regarding Forward-Looking Statements

Certain statements in this press release

constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.

These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects,

which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans,

intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable,

we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual

results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks

and factors that are beyond our control. Such risks and uncertainties for our company include, but are not limited to: needs for

additional capital to fund our operations, an inability or delay in obtaining required regulatory approvals for Coversin and any

other product candidates, which may result in unexpected cost expenditures; risks inherent in drug development in general; uncertainties

in obtaining successful clinical results for Coversin and any other product candidates and unexpected costs that may result therefrom;

failure to realize any value of Coversin and any other product candidates developed and being developed in light of inherent risks

and difficulties involved in successfully bringing product candidates to market; inability to develop new product candidates and

support existing product candidates; the approval by the FDA and EMA and any other similar foreign regulatory authorities of other

competing or superior products brought to market; risks resulting from unforeseen side effects; risk that the market for Coversin

may not be as large as expected; inability to obtain, maintain and enforce patents and other intellectual property rights or the

unexpected costs associated with such enforcement or litigation; inability to obtain and maintain commercial manufacturing arrangements

with third party manufacturers or establish commercial scale manufacturing capabilities; the inability to timely source adequate

supply of our active pharmaceutical ingredients from third party manufacturers on whom the company depends; our inability to obtain

additional capital on acceptable terms, or at all; unexpected cost increases and pricing pressures; uncertainties of cash flows

and inability to meet working capital needs; and risks and other risk factors detailed in our public filings with the U.S. Securities

and Exchange Commission, including our Annual Report on Form 20-F filed on March 31, 2017. Except as otherwise noted, these forward-looking

statements speak only as of the date of this press release and we undertake no obligation to update or revise any of these statements

to reflect events or circumstances occurring after this press release. We caution investors not to place considerable reliance

on the forward-looking statements contained in this press release.

Susan Forman / Laura Radocaj